Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes.

Trial Profile

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Hypertension; Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Dec 2014 The primary endpoint has been changed from effects of sustained elevations of FFA on blood pressure and endothelial function to changes in systolic blood pressure with change in assessment duration from 2 years to 48 hrs as per ClinicalTrials.gov.
    • 07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top